FROS IN THE NEWS

Cyberknife Center of Flushing Radiation Oncology Celebrates 1 year Anniversary

Study Demonstrates Long-Term Efficacy of Five-Day Course of CyberKnife Prostate Treatment

The Cyberknife Center of Flushing Radiation Oncology celebrated a successful first year of offering patients the most advanced technology in fighting cancer in New York City.


The Cyberknife Center of Flushing Radiation Oncology kicked off the event with presentations by world-renowned Radiation Oncologists Dr. James Cox and Dr. Ritsuko Komaki from MD Anderson Cancer Center. The world leader in Cyberknife Radiosurgery for Prostate cancer Dr. Alan Katz presented on his results of treating over 600 Prostate cancer patients with the Cyberknife Radiosurgery System. Also in attendance from First Coast Oncology in Jacksonville, Florida was Radiation Oncologist Dr. Scot Ackerman along with many physicians from all over New York.


The Cyberknife Center of Flushing Radiation Oncology in its first year has treated with the Cyberknife Radiosurgery System: Prostate Cancer, Lung Cancer, Brain Tumors, Spine Cancers, Liver Cancer, Kidney Cancer, Adrenal Cancer, Pancreatic Cancer, Head and Neck Cancers, Breast Cancer, Para-Aortic Lymph Node Metastasis, Recurrent Ovarian Cancer, Trigeminal Neuraglia, Acoustic Neuroma and others.


"In our first year we have attracted patients from as far as Russia and Puerto Rico to be treated by the Cyberknife Radiosurgery System" said John Dileonardo, Chief Operating Officer of Cyberknife Center of Flushing Radiation Oncology.

FROS IN THE NEWS

CyberKnife Named Best New Radiology Device for 2010

February 21, 2011

SUNNYVALE, Calif., Nov. 29, 2010 /PRNewswire/ - Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company's CyberKnife® VSI(TM) System received the 2010 Minnie for Best New Radiology Device from AuntMinnie.com, the largest and most comprehensive community internet site for radiologists and related professionals in the medical imaging industry. Accuray will be presented with the award at the 2010 Radiological Society of North America (RSNA) annual meeting taking place in Chicago, Ill. from November 28 “ December 3, 2010.


"The Minnies awards have been an important barometer of excellence in radiology for the past 11 years," said Brian Casey, editor in chief of AuntMinnie.com. "We're pleased to recognize Accuray's CyberKnife VSI System as the Best New Radiology Device of the year."


Through Accuray's R&D commitment to clinically-driven product enhancements that meet the needs of its customers and improve patient care, the company announced the CyberKnife VSI System in November 2009. The CyberKnife VSI System leverages the versatility, simplicity, and intelligence of the CyberKnife System to broaden the range of treatment options physicians can offer their patients “ from radiosurgery to conventionally fractionated Robotic IMRT(TM). By supporting this full spectrum of fractionation schemes, the CyberKnife VSI System allows for more customized treatment plans based on patient-specific situations and conditions, such as patients requiring re-irradiation of previously treated areas, or patients requiring partial breast irradiation. Cutting-edge product enhancements, including a world-class 1,000 MU/minute X-band linear accelerator and auto-segmentation capabilities, make planning and delivery simple, convenient and fast for routine clinical use.


"We are honored to receive this designation from such an influential industry publication," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "The team at Accuray is incredibly proud of the CyberKnife VSI System and the benefits it brings to helping patients win their fight against cancer."


About the CyberKnife® Robotic Radiosurgery System


The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

FROS IN THE NEWS

CyberKnife Named Best New Radiology Device for 2010

February 21, 2011

SUNNYVALE, Calif., Nov. 29, 2010 /PRNewswire/ - Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the company's CyberKnife® VSI(TM) System received the 2010 Minnie for Best New Radiology Device from AuntMinnie.com, the largest and most comprehensive community internet site for radiologists and related professionals in the medical imaging industry. Accuray will be presented with the award at the 2010 Radiological Society of North America (RSNA) annual meeting taking place in Chicago, Ill. from November 28 “ December 3, 2010.


"The Minnies awards have been an important barometer of excellence in radiology for the past 11 years," said Brian Casey, editor in chief of AuntMinnie.com. "We're pleased to recognize Accuray's CyberKnife VSI System as the Best New Radiology Device of the year."


Through Accuray's R&D commitment to clinically-driven product enhancements that meet the needs of its customers and improve patient care, the company announced the CyberKnife VSI System in November 2009. The CyberKnife VSI System leverages the versatility, simplicity, and intelligence of the CyberKnife System to broaden the range of treatment options physicians can offer their patients “ from radiosurgery to conventionally fractionated Robotic IMRT(TM). By supporting this full spectrum of fractionation schemes, the CyberKnife VSI System allows for more customized treatment plans based on patient-specific situations and conditions, such as patients requiring re-irradiation of previously treated areas, or patients requiring partial breast irradiation. Cutting-edge product enhancements, including a world-class 1,000 MU/minute X-band linear accelerator and auto-segmentation capabilities, make planning and delivery simple, convenient and fast for routine clinical use.


"We are honored to receive this designation from such an influential industry publication," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "The team at Accuray is incredibly proud of the CyberKnife VSI System and the benefits it brings to helping patients win their fight against cancer."


About the CyberKnife® Robotic Radiosurgery System


The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

FROS IN THE NEWS

First Five-Year Outcomes Published on CyberKnife Radiosurgery for Prostate Cancer

February 12, 2011


Study Demonstrates Long-Term Efficacy of Five-Day Course of CyberKnife Prostate Treatment


SUNNYVALE, Calif., Jan. 11, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today the first published five-year outcomes on low risk prostate cancer patients treated with the CyberKnife® Robotic Radiosurgery System. The multi-center study, published in the January 10, 2011 issue of Radiation Oncology, found that 93 percent of patients had no recurrence of their cancer at a median follow-up of five years, a rate that compares favorably to results obtained with other treatment modalities, including surgery and conventional radiation therapy.


The study, "Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: Five-Year Outcomes," combined data from 41 patients treated at Stanford University in Stanford, Calif. and Naples Community Hospital in Naples, Fla. with a median follow-up of five years. The paper represents the longest published study to date on the use of CyberKnife radiosurgery, also referred to as stereotactic body radiotherapy (SBRT), as a treatment approach for clinically localized, low-risk prostate cancer. In addition to demonstrating high five-year disease-free survival rates, the study also found generally low levels of urinary and rectal toxicity following the five-day course of treatment, concluding that CyberKnife radiosurgery can achieve high rates of disease control while sparing critical structures, thereby minimizing undesirable side effects typically associated with prostate cancer treatments and preserving patients' quality of life.


"As a non-invasive treatment option completed in just five visits, stereotactic radiotherapy with the CyberKnife System offers patients the benefits of more rapid recovery, reduced travel costs and less time off work, allowing them to return to their normal, daily routines almost immediately as compared with the standard nine-week course of radiotherapy," said Christopher King, M.D., an author on the study who is now an Associate Professor of Radiation Oncology and Urology at the UCLA School of Medicine. "In addition, because CyberKnife radiosurgery costs less than conventional radiation and avoids the anesthesia and hospital stay associated with surgery, our national health care system benefits from reduced health care costs."


The past 12 months have seen the publication and presentation of numerous shorter term CyberKnife prostate radiosurgery experiences demonstrating encouraging outcomes. This paper supports these outcomes within a long-term follow-up study. Additional this month, the Accuray sponsored multi-center homogeneous prostate study for low and intermediate risk patients, led by the team at the Swedish Cancer Center in Seattle, accrued the final of 294 patients, providing a broad foundation for future long-term multi-center results.


"The publication of five-year clinical outcomes represents a significant milestone for CyberKnife radiosurgery and is important news for physicians to consider when determining the best course of treatment for prostate cancer patients," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "We look forward to this study and other multi-center studies providing additional long-term quality support of CyberKnife prostate radiosurgery outcomes."

 



Contribute!

LOCATIONS

Flushing: 40-22 Main St, 4th Fl,
Flushing, NY 11354
Brooklyn: 1737 Bath Ave
Brooklyn, NY 11214
Manhattan: 47 Essex St.
New York, NY 10002

STAY CONNECTED

Stay in touch with FROS Radiation Oncology & Cyberknife Centers. Join us on Facebook, Twitter and LinkedIn for latest news and info.